

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: May 08, 2018
PDL Changes Effective Date: July 1, 2018



The following changes will be made to the Preferred Drug List (PDL), effective July 1, 2018, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

For a comprehensive PDL, refer to <http://www.medicaid.ms.gov/providers/pharmacy/preferred-drug-list/>.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ANTIRETROVIRALS - COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & INTEGRASE INHIBITORS	BIKTARVY (bictegravir/emtricitabine/tenofovir)
ANTIVIRALS (Oral) ANTI-CYTOMEGALOVIRUS AGENTS	valganciclovir tablets

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ANTIBIOTICS (GI)	SOLOSEC (secnidazole)
ANTIVIRALS (Oral) ANTI-CYTOMEGALOVIRUS AGENTS	PREVYMIS (letermovir)
ANTIVIRALS (Oral) ANTI-CYTOMEGALOVIRUS AGENTS	VALCYTE (valganciclovir)
ANTIVIRALS (Oral) ANTI-CYTOMEGALOVIRUS AGENTS	valganciclovir solution
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	OZEMPIC (semaglutide)
HYPOGLYCEMICS, INSULINS AND RELATED AGENTS	ADMELOG (insulin lispro)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS	STEGLATRO (ertugliflozin)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS COMBINATIONS	SEGLUROMET (ertugliflozin/metformin)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS COMBINATIONS	STEGLUJAN (ertugliflozin/sitagliptin)
NEUROPATHIC PAIN AGENTS	LYRICA CR (pregabalin)
OPIATE DEPENDENCE TREATMENTS	PROBUPHINE (buprenorphine)
OPIATE DEPENDENCE TREATMENTS	SUBLOCADE (buprenorphine)
OPIATE DEPENDENCE TREATMENTS	VIVITROL (naltrexone)